

PACKAGE LEAFLET

Alpramil® 5 mg/50 mg

tablets for dogs weighing at least 0.5 kg

Alpramil® 12.5 mg/125 mg

tablets for dogs weighing at least 5 kg

Alpramil® 20 mg/200 mg

tablets for dogs weighing at least 8 kg

NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:
Alfasan Nederland B.V., Kuipersweg 9, 3449 JA Woerden, The Netherlands

Manufacturer responsible for batch release:

LelyPharma B.V., Zuiveringsweg 42, 8243 PZ Lelystad, The Netherlands

NAME OF THE VETERINARY MEDICINAL PRODUCT

Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg
Alpramil 12.5 mg/125 mg tablets for dogs weighing at least 5 kg
Alpramil 20 mg/200 mg tablets for dogs weighing at least 8 kg
Milbemycin oxime / praziquantel

STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS

Each 5 mg/50 mg tablet contains:

Active substances:
Milbemycin oxime 5.0 mg
Praziquantel 50.0 mg

Light brown with brown spots, round and convex 11 mm tablet with a cross-shaped break line on one side. Tablets can be divided into halves and quarters.

Each 12.5 mg/125 mg tablet contains:

Active substances:
Milbemycin oxime 12.5 mg
Praziquantel 125.0 mg

Light brown with brown spots, round and convex 15 mm tablet.

Each 20 mg/200 mg tablet contains:

Active substances:
Milbemycin oxime 20.0 mg
Praziquantel 200.0 mg

Light brown with brown spots, round and convex 18 mm tablet.

INDICATIONS

Treatment of mixed infections by adult cestodes and nematodes of the following species susceptible to praziquantel and milbemycin oxime:

- Cestodes:
Dipylidium caninum
Taenia spp.
Echinococcus spp.
Mesocestoides spp.
- Nematodes:
Ancylostoma caninum
Toxocara canis
Toxascaris leonina
Trichuris vulpis
Crenosoma vulpis (Reduction of the level of infection)
Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under "Dosage for each species, route(s) and method of administration")
Thelazia callipaeda (see specific treatment schedule under "Dosage for each species, route(s) and method of administration")

The product can also be used in the prevention of heartworm disease (*Dirofilaria immitis*) if concomitant treatment against cestodes is indicated.

CONTRAINDICATIONS

- 5 mg/50 mg tablet: Do not use in dogs weighing less than 0.5 kg.
 - 12.5 mg/125 mg tablet: Do not use in dogs weighing less than 5 kg.
 - 20 mg/200 mg tablet: Do not use in dogs weighing less than 8 kg.
- Do not use in known cases of hypersensitivity to the active substances or to any of the excipients.
See also section on Special warnings (Special precautions for use in animals).

ADVERSE REACTIONS

On very rare occasions, hypersensitivity reactions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhoea, anorexia and drooling) have been observed in dogs after administration of the combination of milbemycin oxime and praziquantel.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. Alternatively you can report via your national reporting system (national system details).

TARGET SPECIES

- 5 mg/50 mg tablet: Dogs weighing at least 0.5 kg
- 12.5 mg/125 mg tablet: Dogs weighing at least 5 kg
- 20 mg/200 mg tablet: Dogs weighing at least 8 kg

DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Oral use.
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.
The product should be administered with or after some food.

Animals should be weighed to ensure accurate dosing. Depending on the bodyweight of the dog and the availability of tablet strengths, practical dosing examples are as follows:

5 mg/50 mg tablet:

Weight (kg)	5 mg/50 mg tablet
0.5 – 2.5	¼ tablet
> 2.5 – 5	½ tablet
> 5 – 10	1 tablet
> 10 – 15	1½ tablets

12,5mg/125 mg tablet:

Weight (kg)	12,5 mg/125 mg tablet
> 5 – 25	1 tablet
> 25 – 50	2 tablets

20 mg/200 mg tablet:

Weight (kg)	20 mg/200 mg tablet
> 8 – 40	1 tablet
> 40 – 80	2 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the product can replace the monovalent product for the prevention of heartworm disease.

For treatment of *Angiostrongylus vasorum* infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the product and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of *Thelazia callipaeda*, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the product can replace the monovalent product containing milbemycin oxime alone.

ADVICE ON CORRECT ADMINISTRATION

The 5 mg/50 mg tablets can be divided into halves and quarters to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.

Halves: press down with your thumbs on both sides of the tablet:



Quarters: press down with your thumb in the middle of the tablet:



WITHDRAWAL PERIODS

Not applicable.

SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
5 mg/50 mg tablet: Shelf life of divided tablets after first opening of the immediate packaging: 7 days.

SPECIAL WARNINGS

Special warnings for each target species:

The use of the product should follow the implementation of appropriate diagnostic measures towards mixed infections by nematodes and cestodes with consideration of animal history and characteristics (e.g. age, health status), environment (e.g. kennelled dogs, hunting dogs), feeding (e.g. access to raw meat), geographical location and travel. Judgement of the administration of the product in dogs at risk from mixed re-infections or in specific at risk situations (such as zoonotic risks), should be made by the veterinarian responsible.

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the dog should be taken into account, and it is recommended to seek professional advice.

It is recommended to treat all the animals living in the same household concomitantly.

When infection with the cestode *D. caninum* has been confirmed, concomitant treatment against intermediate hosts, such as fleas and lice, should be discussed with a veterinarian to prevent re-infection.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. Unnecessary use of antiparasitics or use deviating from the instructions may increase the resistance selection pressure and lead to reduced efficacy. In third countries (USA), resistance of *Dipylidium caninum* to praziquantel as well as cases of multiple-drug resistance of *Ancylostoma caninum* to milbemycin oxime have already been reported.

Special precautions for use in animals:

Studies with milbemycin oxime indicate that the margin of safety in MDR1 mutant (-/-) dogs of Collie or related breeds is lower in young compared to the normal population. In these dogs, the recommended dose should be strictly observed. The tolerance of the veterinary medicinal product in pure bred puppies for these breeds has not been investigated. Clinical signs in these dogs are similar to those seen in the general dog population (see Adverse Reactions).

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using the veterinary medicinal product, a veterinary consultation is advised to exclude the presence of any concurrent infestation of *Dirofilaria immitis*. In the case of a positive diagnosis, adjuvant therapy is indicated before administering the veterinary medicinal product.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may be harmful when ingested, particularly for children.
Avoid accidental ingestion.
Any unused tablet parts of 5 mg/50 mg tablets should be discarded or returned to the open blister, inserted back into the outer packaging and used at the next administration. The product should be stored in a safe place.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.

Other precautions:

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation of Animal Health (OIE), specific guidelines on the treatment and follow-up and on the safeguard of persons need to be obtained from the relevant competent authority.

Pregnancy and lactation:

The product can be used in breeding dogs including pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction:

The concurrent use of the product with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the product at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the product and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Overdose (symptoms, emergency procedures, antidotes):

No other signs than those observed at the recommended dose have been observed (see Adverse Reactions).

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. The product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

30 March 2022

OTHER INFORMATION

OPA/Aluminium/PVC-Aluminium blister containing 1, 2 or 4 tablets.

- Box with 1 blister containing 1 tablet.
- Box with 1 blister containing 2 tablets.
- Box with 1 blister containing 4 tablets.
- Box with 10 blisters each containing 1 tablet.
- Box with 10 blisters each containing 2 tablets.
- Box with 10 blisters each containing 4 tablets.
- Box with 25 blisters each containing 1 tablet.
- Box with 25 blisters each containing 2 tablets.
- Box with 25 blisters each containing 4 tablets.

Not all pack sizes may be marketed.

REG NL 128001 / REG NL 128002 / REG NL 128003

LEGAL STATUS

VRIJ - Available without prescription.